Targetingmitochondria for neuroprotection in parkinson disease

JAMA Neurology

Volumn 71, Issue 5, 2014, Pages 537-538

  Schapira, Anthony H V ^a   Patel, Sandip ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; PARKIN; PLACEBO; UBIDECARENONE; ANTIOXIDANT; DRUG DERIVATIVE; UBIQUINONE;

CALCIUM SIGNALING; CELL FUNCTION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG TARGETING; DRUG TREATMENT FAILURE; EDITORIAL; HUMAN; MITOCHONDRION; MITOPHAGY; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME; FEMALE; MALE; NOTE;

ANTIOXIDANTS; FEMALE; HUMANS; MALE; PARKINSON DISEASE; UBIQUINONE;

EID: 84900507127     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.64     Document Type: Editorial

References (29)

1. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD.Mitochondrial complex I deficiency in Parkinsons disease. Lancet. 1989;1(8649):1269.
2. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD.Mitochondrial complex I deficiency in Parkinsons disease. J Neurochem. 1990;54(3):823-827.
3. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinsons disease. Lancet Neurol. 2008;7(1):97-109.
4. Houlden H, Singleton AB. The genetics and neuropathology of Parkinsons disease. Acta Neuropathol. 2012;124(3):325-338.
5. Shults CW, Oakes D, Kieburtz K, et al; Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease. Arch Neurol. 2002;59(10):1541- 1550.
6. The Parkinson Study Group QE3 Investigators. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit [published online March 24, 2014]. JAMA Neurol. doi:10.1001/jamaneurol.2014.131.
7. Storch A, Jost WH, Vieregge P, et al; German Coenzyme Q(10) Study Group. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol. 2007;64(7): 938-944.
8. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68(1):20-28.
9. Schapira AH, McDermottMP, Barone P, et al. Pramipexole in patients with early Parkinsons disease (PROUD). Lancet Neurol. 2013;12(8):747-755.
10. Olanow CW, Rascol O, Hauser R, et al; ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361(13):1268-1278.
11. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntingtons disease. Neurology. 2001;57(3):397-404.
12. Hart PE, Lodi R, Rajagopalan B, et al. A ntioxidant treatment of patients with Friedreich ataxia. Arch Neurol. 2005;62(4):621-626.
13. Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AH. Coenzyme Q10 and vitamin E deficiency in Friedreichs ataxia. Eur J Neurol. 2008;15(12):1371-1379.
14. Bradley JL, Blake JC, Chamberlain S, Thomas PK, Cooper JM, Schapira AH. Clinical, biochemical and molecular genetic correlations in Friedreichs ataxia. Hum Mol Genet. 2000;9(2):275-282.
15. Snow BJ, Rolfe FL, Lockhart MM, et al; Protect Study Group. A double-blind, placebo-controlled study to assess themitochondria-targeted antioxidant MitoQ as a disease-modifying therapy i n Parkinsons disease. Mov Disord.2010;25(11):1670-1674.
16. Cho DH, Nakamura T, Lipton SA. Mitochondrial dynamics in cell death and neurodegeneration. Cell Mol Life Sci. 2010;67(20):3435-3447.
17. GeggME, Cooper JM, Chau KY, RojoM, Schapira AH, Taanman JW.Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction ofmitophagy. Hum Mol Genet. 2010;19(24):4861-4870.
18. Gegg ME, Schapira AH. PINK1-parkindependent mitophagy involves ubiquitination of mitofusins 1 and 2. Autophagy. 2011;7(2):243-245.
19. Tain LS, Mortiboys H, Tao RN, Ziviani E, Bandmann O, Whitworth AJ. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci. 2009;12(9):1129-1135.
20. Duchen MR, Szabadkai G. Roles of mitochondria in human disease. Essays Biochem. 2010;47:115-137.
21. Guzman JN, Snchez-Padilla J, Chan CS, Surmeier DJ. Robust pacemaking in substantia nigra dopaminergic neurons. J Neurosci. 2009;29(35):11011-11019.
22. Guzman JN, Sanchez-Padilla J,Wokosin D, et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature. 2010;468(7324):696-700.
23. Cal T, Ottolini D, Brini M. Mitochondrial Ca(2+) and neurodegeneration. Cell Calcium. 2012;52(1):73-85.
24. Kilpatrick BS, Eden ER, Schapira AH, Futter CE, Patel S. Direct mobilisation of lysosomal Ca2+ triggers complex Ca2+ signals. J Cell Sci. 2013;126(pt 1):60-66.
25. Gómez-Suaga P, Luzón-Toro B, Churamani D, et al. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet. 2012;21(3):511-525.
26. Patel S, Marchant JS, Brailoiu E. Two-pore channels. Cell Calcium. 2010;47(6):480-490.
27. Parkinson Study Group. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinsons disease (STEADY-PD). Mov Disord. 2013;28(13):1823-1831.
28. Schapira AH, Olanow CW, Greenamyre JT, Bezard E. Slowing neurodegeneration in Parkinsons disease and Huntingtons disease: therapeutic perspective. Lancet. In press.
29. Schapira AH. Calcium dysregulation in Parkinsons disease. Brain. 2013;136(pt 7):2015-2016.